In a pioneering phase 3 clinical trial in severe VWD, rVWF was initially administered together with rFVIII at a ratio of 1.3 : 1.0 ± 0.2 VWF:RCo/FVIII:C. The gene discussed is F8; the disease is von Willebrand disease (hereditary or acquired).